TNM stage in the Nordic Cancer Registries 2004–2016: Registration and availability
DOI:
https://doi.org/10.2340/1651-226X.2024.35232Keywords:
TNM, Cancer Stage, Cancer Registries, NORDCAN, relative survivalAbstract
Background and purpose: Stage at cancer diagnosis is an important predictor of cancer survival. TNM stage is constructed for anatomic solid cancer diagnoses from tumor size (T), nodal spread (N) and distant metastasis (M) and categorized in groups 0–I, II, II and IV. TNM stage is imperative in cancer diagnosis, management and control, and of high value in cancer surveillance, for example, monitoring of stage distributions. This study yields an overview of TNM availability and trends in stage distribution in the Nordic countries for future use in monitoring and epidemiologic studies.
Material and methods: TNM information was acquired from the cancer registries in Denmark, Norway, Sweden, and Iceland during 2004–2016 for 26 cancer sites in the three former countries and four in Iceland. We studied availability, comparability, and distribution of TNM stage in three periods: 2004–2008, 2009–2013, and 2014–2016, applying a previously validated algorithm of ‘N0M0 for NXMX’. For cancers of colon, rectum, lung, breast, and kidney, we examined TNM stage-specific 1-year relative survival to evaluate the quality in registration of TNM between countries.
Results: Denmark, Sweden, and Iceland exhibited available TNM stage proportions of 75–95% while proportions were lower in Norway. Proportions increased in Sweden over time but decreased in Denmark. One-year relative survival differed substantially more between TNM stages than between countries emphasizing that TNM stage is an important predictor for survival and that stage recording is performed similarly in the Nordic countries.
Interpretation: Assessment and registration of TNM stage is an imperative tool in evaluations of trends in cancer survival between the Nordic countries.
Downloads
References
Kerr DJ, Haller DG, van de Velde CJH, Baumann M, eds. Oxford textbook of oncology, 3th ed. New York (NY): Oxford University Press; 2016. DOI: https://doi.org/10.1093/med/9780199656103.001.0001
Brierley J, O’Sullivan B, Asamura H, Byrd D, Huang SH, Lee A, et al. Global Consultation on Cancer Staging: promoting consistent understanding and use. Nat Rev Clin Oncol. 2019;16(12):763–771.
https://doi.org/10.1038/s41571-019-0253-x DOI: https://doi.org/10.1038/s41571-019-0253-x
Engholm G, Lundberg FE, Kønig SM, Ólafsdóttir E, Johannesen TB, Pettersson D, et al. Influence of various assumptions for the individual TNM components on the TNM stage using Nordic cancer registry data. Acta Oncol. 2023;62(3):215–222.
https://doi.org/10.1080/0284186X.2023.2189528 DOI: https://doi.org/10.1080/0284186X.2023.2189528
Pukkala E, Engholm G, Højsgaard Schmidt LK, Storm H, Khan S, Lambe M, et al. Nordic Cancer Registries – an overview of their procedures and data comparability. Acta Oncol. 2018;57(4):440–455.
https://doi.org/10.1080/0284186X.2017.1407039. DOI: https://doi.org/10.1080/0284186X.2017.1407039
Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–736.
https://doi.org/10.3109/02841861003782017 DOI: https://doi.org/10.3109/02841861003782017
Larønningen S, Arvidsson G, Bray F, Engholm G, Ervik M, Guðmundsdóttir EM, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the nordic countries, Version 9.3 (02.10.2023). Association of the Nordic Cancer Registries. Cancer Registry of Norway; 2023 [cited 2023 Dec 02] Available from: https://nordcan.iarc.fr/
Larønningen S, Skog A, Engholm G, Ferlay J, Johannesen TB, Kristiansen MF, et al. Nordcan.R: a new tool for federated analysis and quality assurance of cancer registry data. Front. Oncol. 2023;13:1098342.
https://doi.org/10.3389/fonc.2023.1098342 DOI: https://doi.org/10.3389/fonc.2023.1098342
Storm HH, Engholm G, Hakulinen T, Tryggvadóttir L, Klint A, Gislum M, et al. Survival of patients diagnosed with cancer in the Nordic countries up to 1999–2003 followed to the end of 2006. A critical overview of the results. Acta Oncol. 2010;49(5):532–544.
https://doi.org/10.3109/02841861003801148 DOI: https://doi.org/10.3109/02841861003801148
Lundberg FE, Andersson TM, Lambe M, Engholm G, Mørch LS, Johannesen TB, et al. Trends in cancer survival in the Nordic countries 1990–2016: the NORDCAN survival studies. Acta Oncol. 2020;59(11):1266–1274.
https://doi.org/10.1080/0284186X.2020.1822544 DOI: https://doi.org/10.1080/0284186X.2020.1822544
Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39(7 Suppl):42–45.
https://doi.org/10.1177/1403494810393562 DOI: https://doi.org/10.1177/1403494810393562
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
https://doi.org/10.2147/CLEP.S91125 DOI: https://doi.org/10.2147/CLEP.S91125
Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health. 2011;39:72–74.
https://doi.org/10.1177/1403494810393563 DOI: https://doi.org/10.1177/1403494810393563
Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39(7 Suppl):26–29.
https://doi.org/10.1177/1403494811399958 DOI: https://doi.org/10.1177/1403494811399958
Nilbert M, Thomsen LA, Winther Jensen J, Møller H, Borre M, Widenlou Nordmark A, et al. The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care. Acta Oncol. 2020;59(11):1343–1356.
https://doi.org/10.1080/0284186X.2020.1820573 DOI: https://doi.org/10.1080/0284186X.2020.1820573
Om INCA (In Swedish). [cited 2023 Aug 31]. Available from: https://cancercentrum.se/mellansverige/vara-uppdrag/kunskapsstyrning/kvalitetsregister/om-inca/
Registration and Research>Quality registration of Cancer. [cited 2023 Dec 19]. Available from: https://www.krabb.is/rannsoknasetur/en
Sobin LH, Wittekind C, eds. International Union Against Cancer (UICC). TNM classification of malignant tumors. 5th ed. New York: John Wiley & Sons, Inc.; 1997.
Sobin LH, Wittekind C, eds. TNM Classification of malignant tumours, 6th ed. New York: Wiley-Liss; 2002. DOI: https://doi.org/10.1002/0471463752
Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM classification of malignant tumours, 7th ed. Chichester: Wiley; 2009. DOI: https://doi.org/10.1002/9780471420194.tnmc26
Rutherford MJ, Dickman PW, Coviello E, Lambert PC. Estimation of age-standardized net survival, even when age-specific data are sparse. Cancer Epidemiol. 2020;67:101745.
https://doi.org/10.1016/j.canep.2020.101745 DOI: https://doi.org/10.1016/j.canep.2020.101745
Lambert P. STPP: Stata module to compute Pohar-Perme non-parametric estimate of marginal relative (net) survival. Statistical Software Components S458743. Boston College Department of Economics; Boston; 2020 Revised 05 January 2024.
Meyer HJ, Pfeil A, Schramm D, Bach AG, Surov A. Renal incidental findings on computed tomography: Frequency and distribution in a large non selected cohort. Medicine (Baltimore). 2017 Jun;96(26):e7039.
https://doi.org/10.1097/MD.0000000000007039 DOI: https://doi.org/10.1097/MD.0000000000007039
DARENCA data yearly report 1/8/2015-31/7/2016 (In Danish) Page 82. [cited 2023 Sep 01]. Available from: https://ducg.dk/fileadmin/www.ducg.dk/Nyrecancer/DaRenCa_AArsrapport_2016_Offentliggoerelse_3_0.pdf
Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians – a national Danish project. Health Policy. 2012 Apr;105(1):65–70.
https://doi.org/10.1016/j.healthpol.2011.11.001 DOI: https://doi.org/10.1016/j.healthpol.2011.11.001
Dyrop HB, Safwat A, Vedsted P, Maretty-Nielsen K, Hansen BH, Jørgensen PH, et al. Cancer patient pathways shortens waiting times and accelerates the diagnostic process of suspected sarcoma patients in Denmark. Health Policy. 2013 Nov;113(1–2):110–117.
https://doi.org/10.1016/j.healthpol.2013.09.012 DOI: https://doi.org/10.1016/j.healthpol.2013.09.012
Nilssen Y, Brustugun OT, Tandberg Eriksen M, Gulbrandsen J, Skaaheim Haug E, Naume B, et al. Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway. Cancer Epidemiol. 2019 Aug;61:59–69.
https://doi.org/10.1016/j.canep.2019.05.004 DOI: https://doi.org/10.1016/j.canep.2019.05.004
Lundberg FE, Kroman N, Lambe M, Andersson TM, Engholm G, Johannesen TB, et al. Age-specific survival trends and life-years lost in women with breast cancer 1990–2016: the NORDCAN survival studies. Acta Oncol. 2022;61(12):1481–1489.
https://doi.org/10.1080/0284186X.2022.2156811 DOI: https://doi.org/10.1080/0284186X.2022.2156811
Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985 Jun;312(25):1604–1608.
https://doi.org/10.1056/NEJM198506203122504 DOI: https://doi.org/10.1056/NEJM198506203122504
Additional Files
Published
How to Cite
License
Copyright (c) 2023 Gerda Engholm, Frida E. Lundberg, Simon M. Kønig, Elínborg Ólafsdóttir, Tom B. Johannesen, David Pettersson, Nea Malila, Lina S. Mørch, Anna L.V. Andersson, Søren Friis
This work is licensed under a Creative Commons Attribution 4.0 International License.
